Hepatic and Cardiac Steatosis: Are They Coupled?

Heart Failure Clinics

Volumn 8, Issue 4, 2012, Pages 663-670

  Bugianesi, Elisabetta ^a   Gastaldelli, Amalia ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

Author keywords

Cardiac steatosis; Coronary artery disease; Hepatic steatosis; Nonalcoholic fatty liver disease

Indexed keywords

ADIPONECTIN; ALANINE AMINOTRANSFERASE; C REACTIVE PROTEIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GAMMA GLUTAMYLTRANSFERASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; LEPTIN; LOW DENSITY LIPOPROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; OXIDIZED LOW DENSITY LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; REACTIVE OXYGEN METABOLITE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANGIOCARDIOGRAPHY; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIAC STEATOSIS; CARDIOMETABOLIC RISK; CARDIOVASCULAR MORTALITY; COMPUTER ASSISTED TOMOGRAPHY; CONFIDENCE INTERVAL; CORONARY ARTERY CALCIFICATION; CORONARY ARTERY DISEASE; CORONARY RISK; DIABETIC PATIENT; DIASTOLIC DYSFUNCTION; ECHOGRAPHY; ENDOTHELIAL DYSFUNCTION; FATTY LIVER; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLUCONEOGENESIS; GOLD STANDARD; HEART FUNCTION; HEART MUSCLE METABOLISM; HUMAN; INSULIN DEGRADATION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIPID STORAGE; LIVER BIOPSY; METABOLIC SYNDROME X; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OXIDATIVE STRESS; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PREDICTION; PREVALENCE; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; STEATOSIS;

CORONARY ARTERY DISEASE; DISEASE PROGRESSION; FATTY LIVER; HUMANS; INSULIN RESISTANCE; LIPOLYSIS; LIVER; METABOLIC SYNDROME X; MYOCARDIUM; RISK FACTORS; TRIGLYCERIDES;

EID: 84866629592     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2012.06.010     Document Type: Review

References (49)

1. Falck-Ytter Y., Younossi Z.M., Marchesini G., et al. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis 2001, 21(1):17-26.
2. de Alwis N.M., Day C.P. Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol 2008, 48(Suppl 1):S104-S112.
3. Bellentani S., Saccoccio G., Masutti F., et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000, 132(2):112-117.
4. Mofrad P., Contos M.J., Haque M., et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003, 37(6):1286-1292.
5. Ricci C., Longo R., Gioulis E., et al. Noninvasive in vivo quantitative assessment of fat content in human liver. J Hepatol 1997, 27(1):108-113.
6. Sironi A.M., Petz R., De Marchi D., et al. Impact of increased visceral and cardiac fat on cardiometabolic risk and disease. Diabet Med 2012, 29(5):622-627.
7. Sironi A.M., Gastaldelli A., Mari A., et al. Visceral fat in hypertension: influence on insulin resistance and beta-cell function. Hypertension 2004, 44(2):127-133.
8. Sacks H.S., Fain J.N. Human epicardial adipose tissue: a review. Am Heart J 2007, 153(6):907-917.
9. Sironi A.M., Sicari R., Folli F., et al. Ectopic fat storage, insulin resistance, and hypertension. Curr Pharm Des 2011, 17(28):3074-3080.
10. Targher G., Day C.P., Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010, 363(14):1341-1350.
11. Ghouri N., Preiss D., Sattar N. Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: a narrative review and clinical perspective of prospective data. Hepatology 2010, 52(3):1156-1161.
12. Perseghin G. The role of non-alcoholic fatty liver disease in cardiovascular disease. Dig Dis 2010, 28(1):210-213.
13. Gastaldelli A., Kozakova M., Hojlund K., et al. Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology 2009, 49(5):1537-1544.
14. Kozakova M., Palombo C., Paterni M., et al. Fatty liver index, gamma-glutamyltransferase and early carotid plaques. Hepatology 2012, 55(5):1406-1415.
15. Schindhelm R.K., Dekker J.M., Nijpels G., et al. Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study. Atherosclerosis 2007, 191(2):391-396.
16. Goessling W., Massaro J.M., Vasan R.S., et al. Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease. Gastroenterology 2008, 135(6):1935-1944.
17. Fraser A., Harris R., Sattar N., et al. Gamma-glutamyltransferase is associated with incident vascular events independently of alcohol intake: analysis of the British Women's Heart and Health Study and Meta-Analysis. Arterioscler Thromb Vasc Biol 2007, 27(12):2729-2735.
18. Paolicchi A., Emdin M., Ghliozeni E., et al. Images in cardiovascular medicine. Human atherosclerotic plaques contain gamma-glutamyl transpeptidase enzyme activity. Circulation 2004, 109(11):1440.
19. Paolicchi A., Minotti G., Tonarelli P., et al. Gamma-glutamyl transpeptidase-dependent iron reduction and LDL oxidation-a potential mechanism in atherosclerosis. J Investig Med 1999, 47(3):151-160.
20. Targher G., Bertolini L., Padovani R., et al. Relation of nonalcoholic hepatic steatosis to early carotid atherosclerosis in healthy men: role of visceral fat accumulation. Diabetes Care 2004, 27(10):2498-2500.
21. Targher G., Bertolini L., Padovani R., et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 2007, 30(5):1212-1218.
22. Lin Y.C., Lo H.M., Chen J.D. Sonographic fatty liver, overweight and ischemic heart disease. World J Gastroenterol 2005, 11(31):4838-4842.
23. Mirbagheri S.A., Rashidi A., Abdi S., et al. Liver: an alarm for the heart?. Liver Int 2007, 27(7):891-894.
24. Wong V.W., Wong G.L., Yip G.W., et al. Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease. Gut 2011, 60(12):1721-1727.
25. Ding J., Kritchevsky S.B., Harris T.B., et al. The association of pericardial fat with calcified coronary plaque. Obesity (Silver Spring) 2008, 16(8):1914-1919.
26. Djaberi R., Schuijf J.D., van Werkhoven J.M., et al. Relation of epicardial adipose tissue to coronary atherosclerosis. Am J Cardiol 2008, 102(12):1602-1607.
27. Ekstedt M., Franzen L.E., Mathiesen U.L., et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006, 44(4):865-873.
28. Soderberg C., Stal P., Askling J., et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010, 51(2):595-602.
29. Fotbolcu H., Yakar T., Duman D., et al. Impairment of the left ventricular systolic and diastolic function in patients with non-alcoholic fatty liver disease. Cardiol J 2010, 17(5):457-463.
30. Perseghin G., Ntali G., De Cobelli F., et al. Abnormal left ventricular energy metabolism in obese men with preserved systolic and diastolic functions is associated with insulin resistance. Diabetes Care 2007, 30(6):1520-1526.
31. Rijzewijk L.J., Jonker J.T., van der Meer R.W., et al. Effects of hepatic triglyceride content on myocardial metabolism in type 2 diabetes. J Am Coll Cardiol 2010, 56(3):225-233.
32. Lautamaki R., Borra R., Iozzo P., et al. Liver steatosis coexists with myocardial insulin resistance and coronary dysfunction in patients with type 2 diabetes. Am J Physiol Endocrinol Metab 2006, 291(2):E282-E290.
33. Boudina S., Abel E.D. Diabetic cardiomyopathy revisited. Circulation 2007, 115(25):3213-3223.
34. Kotronen A., Westerbacka J., Bergholm R., et al. Liver fat in the metabolic syndrome. J Clin Endocrinol Metab 2007, 92(9):3490-3497.
35. Bugianesi E., McCullough A.J., Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 2005, 42(5):987-1000.
36. Perseghin G., Lattuada G., De Cobelli F., et al. Increased mediastinal fat and impaired left ventricular energy metabolism in young men with newly found fatty liver. Hepatology 2008, 47(1):51-58.
37. Kankaanpaa M., Lehto H.R., Parkka J.P., et al. Myocardial triglyceride content and epicardial fat mass in human obesity: relationship to left ventricular function and serum free fatty acid levels. J Clin Endocrinol Metab 2006, 91(11):4689-4695.
38. Iacobellis G., Barbaro G. The double role of epicardial adipose tissue as pro- and anti-inflammatory organ. Hormone and metabolic research. Horm Metab Res 2008, 40(7):442-445.
39. Iacobellis G., Sharma A.M. Epicardial adipose tissue as new cardio-metabolic risk marker and potential therapeutic target in the metabolic syndrome. Curr Pharm Des 2007, 13(21):2180-2184.
40. Iacobellis G., Assael F., Ribaudo M.C., et al. Epicardial fat from echocardiography: a new method for visceral adipose tissue prediction. Obes Res 2003, 11(2):304-310.
41. Sicari R., Sironi A.M., Petz R., et al. Pericardial rather than epicardial fat is a cardiometabolic risk marker: an MRI vs echo study. J Am Soc Echocardiogr 2011, 24(10):1156-1162.
42. Tripathy D., Mohanty P., Dhindsa S., et al. Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects. Diabetes 2003, 52(12):2882-2887.
43. Mullenix P.S., Andersen C.A., Starnes B.W. Atherosclerosis as inflammation. Ann Vasc Surg 2005, 19(1):130-138.
44. Bertolani C., Marra F. The role of adipokines in liver fibrosis. Pathophysiology 2008, 15(2):91-101.
45. Paolisso G., Tagliamonte M.R., Galderisi M., et al. Plasma leptin level is associated with myocardial wall thickness in hypertensive insulin-resistant men. Hypertension 1999, 34(5):1047-1052.
46. Del Turco S., Navarra T., Gastaldelli A., et al. Protective role of adiponectin on endothelial dysfunction induced by AGEs: a clinical and experimental approach. Microvasc Res 2011, 82(1):73-76.
47. Fontana L., Eagon J.C., Trujillo M.E., et al. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes 2007, 56(4):1010-1013.
48. Gastaldelli A., Cusi K., Pettiti M., et al. Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. Gastroenterology 2007, 133(2):496-506.
49. Despres J.P., Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006, 444(7121):881-887.